Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Richard A. Smykla · SciRah

Researcher profile · Semantic Scholar

Richard A. Smykla

Share profile

Richard A. Smykla — researcher profile on SciRah

h-index: 13
Works: 18
Citations: 1,259

Most-cited papers

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
K. Porkka, P. Koskenvesa, T. Lundán, J. Rimpiläinen +21 more
2008Blood445 citations Open access
Semantic Scholar
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
F. Luo, Zheng Yang, Amy Camuso, Richard A. Smykla +10 more
2006Clinical Cancer Research151 citations
Semantic Scholar
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
F. Lee, R. Borzilleri, C. Fairchild, Amrita V. Kamath +3 more
2008Cancer Chemotherapy and Pharmacology115 citations Open access
Semantic Scholar
Preclinical efficacy spectrum and pharmacokinetics of ixabepilone
F. Lee, Richard A. Smykla, Kathy A. Johnston, Krista Menard +6 more
2008Cancer Chemotherapy and Pharmacology105 citations Open access
Semantic Scholar
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
S. Mustjoki, Kaisa Auvinen, A. Kreutzman, P. Rousselot +12 more
2013Leukemia91 citations
Semantic Scholar
In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models
J. K. Peterson, C. Tucker, Edward Favours, P. Cheshire +5 more
2005Clinical Cancer Research85 citations
Semantic Scholar
Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling
T. Wong, F. Lee, Chiang Yu, F. Luo +8 more
2006Clinical Cancer Research73 citations Open access
Semantic Scholar
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor
F. Luo, Y. Barrett, Zheng Yang, Amy Camuso +9 more
2008Cancer Chemotherapy and Pharmacology51 citations Open access
Semantic Scholar
Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models
Can Hekim, M. Ilander, Jun Yan, E. Michaud +10 more
2017Cancer immunology research47 citations
Semantic Scholar
Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models
V. Manne, F. Lee, D. Bol, J. Gullo-Brown +8 more
2004Cancer Research28 citations
Semantic Scholar
Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).
F. Lee, Mei-Li Wen, R. Bhide, Amy Camuso +11 more
200520 citations
Semantic Scholar
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy
Jin-Ming Yang, Snjezana Zaja-Milatovic, Y. Thu, F. Lee +2 more
2009Molecular Cancer Therapeutics18 citations Open access
Semantic Scholar
BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.
R. Wild, S. Castaneda, C. Flefleh, Krista Fager +11 more
200415 citations
Semantic Scholar
Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.
S. Mustjoki, P. Rousselot, S. Jalkanen, A. Kreutzman +8 more
20107 citations
Semantic Scholar
Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.
F. Lee, Mei-Li Wen, Amy Camuso, Stephen Castenada +10 more
20055 citations
Semantic Scholar
Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.
F. Luo, Zheng Yang, Amy Camuso, Richard A. Smykla +12 more
20043 citations
Semantic Scholar
Dasatinib potential for anti-inflammatory efficacy while avoiding suppression of T cell activation in preclinical models (33.8)
G. Schieven, Rosemary F Zhang, Sidney Pitt, K. McIntyre +6 more
2009Journal of Immunology1 citations
Semantic Scholar
Dasatinib Once-Daily Dose Regimen Provides Robust Anti-Leukemic Activity While Avoiding Suppression of T Cell Activation.
G. Schieven, Rosemary F Zhang, Sidney Pitt, K. McGlinchey +7 more
20090 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Lee×17
Invite
F. Lee — researcher profile on SciRah
K. McGlinchey×8
Invite
K. McGlinchey — researcher profile on SciRah
Mei-Li Wen×8
Invite
Mei-Li Wen — researcher profile on SciRah
Amy Camuso×6
Invite
Amy Camuso — researcher profile on SciRah

×6

Invite

Krista Fager — researcher profile on SciRah

Invite

R. Wild — researcher profile on SciRah

Invite

F. Luo — researcher profile on SciRah

Invite

C. Flefleh — researcher profile on SciRah

Invite

I. Inigo — researcher profile on SciRah

Invite

D. Kan — researcher profile on SciRah

Invite

K. Porkka — researcher profile on SciRah

Invite

S. Mustjoki — researcher profile on SciRah